Influence of Nano-Carrier Architecture onin VitrosiRNA Delivery Performance andin VivoBiodistribution: PolyplexesvsMicelleplexes
Citations Over TimeTop 10% of 2011 papers
Abstract
Micelle-based siRNA carriers ("micelleplexes") were prepared from the A-B-C triblock copolymer poly(ethylene glycol)-poly(n-butyl acrylate)-poly(2-(dimethylamino)ethyl methacrylate) (PEG-PnBA-PDMAEMA), and their in vitro performance and in vivo biodistribution properties were compared with the benchmark PEGylated and basic polycation systems PEG-PDMAEMA and PDMAEMA, respectively. The micelle architecture, incorporating increased PEG shielding and a larger particle size (∼50 nm) than polycation-based complexes (polyplexes; ∼10 nm), enhances siRNA delivery performance in two important aspects: in vitro gene silencing efficiency and in vivo tumor accumulation. The in vitro gene silencing efficiency of the micelleplexes (24% in HeLa cells) was significantly better than the statistically insignificant levels observed for PDMAEMA and PEG-PDMAEMA polyplexes under identical conditions. This enhancement is linked to the different mechanisms by which micelleplexes are internalized (i.e., caveolar, etc.) compared to PDMAEMA and PEG-PDMAEMA polyplexes. Folate-functionalization significantly improved micelleplex uptake but had negligible influence on gene-silencing efficiency, suggesting that this parameter is not limited by cellular internalization. In vivo biodistribution analysis revealed that siRNA delivered by micelleplexes was more effectively accumulated and retained in tumor tissues than that delivered by PEGylated polyplexes. Overall, the micelle particle size and architecture appear to improve in vitro and in vivo delivery characteristics without significantly changing other properties, such as cytotoxicity and resistance to enzymes and dissociation. The self-assembled nature of micelleplexes is expected to enable incorporation of imaging modalities inside the hydrophobic micelle core, thus combining therapeutic and diagnostic capabilities. The findings from the present study suggest that the micelleplex-type carrier architecture is a useful platform for potential theranostic and tumor-targeting applications.
Related Papers
- → Peptide and protein PEGylation(2001)1,048 cited
- → Application of microchip CGE for the analysis of PEG‐modified recombinant human granulocyte‐colony stimulating factors(2010)16 cited
- → PEGylated Antibodies and DNA in Organic Media and Genetic PEGylation(2013)1 cited
- Gene silencing efficiency of siRNA-PEG conjugates : effect of PEGylation site and PEG molecular weight = PEGylation site와 PEG 분자량이 siRNA-PEG conjugate의 유전자 발현 억제에 미치는 영향에 관한 연구(2010)
- → Author Index for Volume 376, Number 1(2000)